Transmed Biomedical

Shenzhen Transmed Biomedical Co., Ltd. is a high-tech enterprise focusing on the biomedical field. The enterprise was jointly initiated by senior experts in the medical industry and has gathered outstanding talents from various fields of biology and medicine. Shenzhen Transmed Biomedical was founded in Shenzhen in 2017, jointly established by senior cross-industry talents in industry, technology and capital. Relying on product innovation technology with independent intellectual property rights, and based on product innovation and quality design, the enterprise focuses on providing customers with leading medical device products and services. At its inception, Transmed Biomedical received a joint angel round investment of nearly 20 million yuan from several well-known industry venture capital firms including CAS Star, Tsinghua Leaguer, Kaiying Capital and Xiantong Capital. Transmed Biomedical mainly focuses on the R&D, production and market development of innovative POCT product platforms and fully automated in vitro diagnostic analysis and testing platforms. Transmed Biomedical possesses a reserve of patented technologies and has deep resource accumulation and industrialization advantages in multiple directions including instruments, reagents and markets. Driven by product innovation and taking quality as its lifeline, Transmed Biomedical is committed to building a global brand of national medical devices, contributing to the revitalization of national medical devices, and creating value for customers, society and shareholders. At present, the company's 2,500㎡ instrument R&D and production base, reagent R&D and production base and GMP workshop have been completed and put into use.